Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

You are here: Industry Insights > Mirati Therapeutics

News List

Boehringer, Mirati Therapeutics Enter Clinical Collaboration contractpharma
September 18, 2020
To evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors.
Strata Oncology, Mirati Announce Partnership for MRTX849 Trial americanpharmaceuticalreview
August 18, 2020
Strata Oncology has signed an agreement with Mirati Therapeutics to broaden patient identification and enrollment for Mirati's Phase 1/2 study of MRTX849 in patients with cancer having a KRAS G12C mutation.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2024 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182 沪公网安备31010402010101号
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go

PharmaSources Customer Service